Clinical Trial Update: Anti-BCMA CAR T-Cell Therapy for R/R ITP [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating anti-BCMA CAR T-cell therapy for relapsed/refractory immune thrombocytopenia (ITP).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Anti-BCMA CAR-T cell therapy

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: ITP | Phase 2 | Status: UNKNOWN